Formosa Laboratories, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 05, 2021 at 04:34 pm
Share
Formosa Laboratories, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was TWD 827.344 million compared to TWD 787.707 million a year ago. Operating loss was TWD 57.084 million compared to TWD 49.020 million a year ago. Net income was TWD 744.629 million compared to TWD 534.173 million a year ago. Basic earnings per share was TWD 6.86 compared to TWD 4.99 a year ago. Diluted earnings per share was TWD 6.14 compared to TWD 4.49 a year ago. For the half year, sales was TWD 1,563.623 million compared to TWD 1,450.350 million a year ago. Operating loss was TWD 126.098 million compared to TWD 97.435 million a year ago. Net income was TWD 1,810.441 million compared to TWD 432.293 million a year ago. Basic earnings per share was TWD 16.7 compared to TWD 4.2 a year ago. Diluted earnings per share was TWD 14.91 compared to TWD 3.78 a year ago.
Formosa Laboratories, Inc. is a Taiwan-based company principally engaged in the development, production and distribution of ultraviolet (UV)-proof active ingredients, bulk pharmaceutical chemicals, antibody drug conjugates, as well as the provision of customized services. The Company primarily provides UV-proof active ingredients series products, vitamin D derivative series products, anti-inflammatory analgesic series products, steroid, anti-cancer drugs, cholesterol phosphate binding agents, nuclear magnetic resonance (NMR) reagents, respiratory disease drugs, central nervous system drugs, immune system regulators and weight loss drugs, as well as customized research and development and original equipment manufacturing (OEM) services. The Company distributes its products to Europe, the Americas, Asia and other markets.
FORMOSA LABORATORIES, INC. 
